Journal article
A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine
Current oncology (Toronto), Vol.31(4), pp.1913-1919
04/01/2024
DOI: 10.3390/curroncol31040143
PMCID: PMC11049499
PMID: 38668046
Abstract
In the past decade, a lot of insight was gathered into the composition of the host and tumor factors that promote oncogenesis and treatment resistance. This in turn has led to the ingenious design of multiple new classes of drugs, which have now become the new standards of care in cancer therapy. These include novel antibody-drug conjugates, chimeric antigen receptor T cell therapies (CAR-T), and bispecific T cell engagers (BitTE). Certain host factors, such as the microbiome composition, are also emerging not only as biomarkers for the response and toxicity to anti-cancer therapies but also as potentially useful tools to modulate anti-tumor responses. The field is slowly moving away from one-size-fits-all treatment options to personalized treatments tailored to the host and tumor. This commentary aims to cover the basic concepts associated with these emerging therapies and the promises and challenges to fight cancer.
Details
- Title: Subtitle
- A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine
- Creators
- Mariana Pilon Capella - Jewish General HospitalKhashayar Esfahani - Jewish General Hospital
- Resource Type
- Journal article
- Publication Details
- Current oncology (Toronto), Vol.31(4), pp.1913-1919
- DOI
- 10.3390/curroncol31040143
- PMID
- 38668046
- PMCID
- PMC11049499
- NLM abbreviation
- Curr Oncol
- ISSN
- 1198-0052
- eISSN
- 1718-7729
- Publisher
- Mdpi
- Number of pages
- 7
- Language
- English
- Date published
- 04/01/2024
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984946623802771
Metrics
9 Record Views